GT BIOPHARMA, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
GT BIOPHARMA, INC. (GTBP) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $53.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-26.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2024-03-26
- GT BIOPHARMA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $52.91M, a 67.88% decline year-over-year.
- GT BIOPHARMA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was -$27.00K, a 128.42% decline year-over-year.
- GT BIOPHARMA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $164.74M.
- GT BIOPHARMA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $95.00K.
- GT BIOPHARMA, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $53.00M, a 67.88% decline from fiscal 2022.
- GT BIOPHARMA, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $165.00M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|---|
| 2023-12-31 | $52.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $52.89M derived: sum of 2 quarters · filed 2024-03-26 | $53.00M 10-K · filed 2024-03-26 | |||
| 2023-09-30 | -$27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $87.00K 10-Q · filed 2023-11-01 | ||||
| 2023-06-30 | $114.00K 10-Q · filed 2023-08-07 | |||||
| 2022-12-31 | $164.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $164.84M derived: sum of 2 quarters · filed 2024-03-26 | -$95.00M derived: sum of 3 quarters · filed 2024-03-26 | $165.00M 10-K · filed 2024-03-26 | ||
| 2022-09-30 | $95.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$259.74M derived: sum of 2 quarters · filed 2023-11-01 | $260.00K 10-Q · filed 2023-11-01 | $260.00M 10-Q · filed 2022-10-31 | ||
| 2022-06-30 | -$259.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $165.00K 10-Q · filed 2023-08-07 | $260.00M 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $260.00M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |